GENFIT Discontinues VS-01 Development in Liver Failure Following Safety Concerns, Refocuses on Rare Disease
核心洞察
GENFIT has discontinued development of its lead liposomal ammonia scavenger VS-01 for acute-on-chronic liver failure (搜索) (ACLF) following a peritonitis (搜索) case reported as a serious adverse event in the Phase II UNVEIL-IT trial.
The company will refocus VS-01 development on urea cycle disorder (搜索) (UCD), a rare genetic condition with significant unmet medical need, where the drug administration and patient population differ substantially from ACLF.
GENFIT plans to accelerate development of four other ACLF assets (G1090N, SRT-015, CLM-022, and VS-02-HE) based on different mechanisms of action and administration routes.
GENFIT has made the strategic decision to discontinue clinical development of VS-01, its liposomal ammonia scavenger, for acute-on-chronic liver failure (搜索) (ACLF) following safety concerns that emerged during Phase II trials. The Lille-headquartered biopharmaceutical company announced it will instead refocus VS-01 development on urea cycle disorder (搜索) (UCD), a rare genetic condition with different risk-benefit considerations.
Safety Signal Prompts Strategic Pivot
The discontinuation follows a peritonitis (搜索) case reported as a Serious Adverse Event (SAE) in the UNVEIL-IT Phase II study, which was evaluating VS-01 in patients with ACLF grades 1, 2, or 3a and ascites. While the independent Data Monitoring Committee (iDMC) concluded that the trial could continue with additional data and monitoring requirements, GENFIT decided to halt both UNVEIL-IT and a proof-of-concept study in hepatic encephalopathy (搜索) after considering the target population's clinical profile and the safety signal's implications for the benefit-risk ratio.
VS-01 is a liposomal formulation designed for intraperitoneal administration to rapidly eliminate ammonia and other toxic metabolites, thereby mitigating liver, kidney, and brain dysfunction. In previous studies involving patients with decompensated liver cirrhosis, single and multiple intraperitoneal administrations of VS-01 demonstrated reductions in blood metabolites associated with ammonia-triggered organ failure in ACLF.
Refocusing on Rare Disease Opportunity
GENFIT will continue preclinical evaluation of VS-01 in UCD, a genetically driven disorder characterized by acute hyperammonemic crisis (HAC). The company emphasized that "the condition, patients and drug administration set-up will be very different from what they were in ACLF." UCD represents a significant unmet medical need, and based on ammonia clearance data, GENFIT believes VS-01 has potential as a therapeutic option for children affected by this disease.
Accelerated ACLF Pipeline Development
Despite discontinuing VS-01 in ACLF, GENFIT remains committed to this therapeutic area, which is characterized by critical unmet medical need with no approved treatment options for patients facing poor prognosis and life-threatening risks. The company plans to accelerate development of four other ACLF assets currently in its pipeline: G1090N, SRT-015, CLM-022, and VS-02-HE. These programs are based on different mechanisms of action and use different routes of administration.
GENFIT expects to deliver safety data and early markers of efficacy on healthy volunteers with G1090N by the end of this year. The company has observed growing interest in the ACLF indication through multiple key opinion leader interactions, with clear support for its clinical strategy.
Financial and Strategic Implications
The discontinuation of GENFIT's lead program will require significant restructuring to substantially reduce operating expenses. However, this provides strategic flexibility, either extending the projected cash runway by at least a year beyond previous guidance to beyond 2028, or enabling exploration of new mechanistic approaches through business development initiatives targeting urgent gaps in ACLF care.
By year-end, GENFIT also aims to share Phase 1b data in cholangiocarcinoma (搜索) (CCA), another life-threatening indication where its novel autophagy/PPT1 inhibitor GNS561 is being evaluated in combination with a MEK inhibitor in CCA with KRAS mutation. CCA is a rare type of biliary tract cancer with high mortality and limited treatment options.
The company's diversified approach reflects its commitment to addressing rare, life-threatening liver diseases while maintaining financial discipline and strategic focus on the most promising therapeutic opportunities.